6-Jan-2026
Mersana Therapeutics Completes Merger and Delists from Nasdaq
TipRanks (Tue, 6-Jan 9:49 AM ET)
Day One Completes Acquisition of Mersana Therapeutics
Globe Newswire (Tue, 6-Jan 9:02 AM ET)
PRNewswire (Tue, 23-Dec 6:55 PM ET)
Globe Newswire (Thu, 18-Dec 3:21 PM ET)
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights
PRNewswire (Wed, 17-Dec 12:06 PM ET)
PRNewswire (Tue, 16-Dec 11:31 AM ET)
Globe Newswire (Sun, 14-Dec 1:10 PM ET)
PRNewswire (Fri, 12-Dec 4:42 PM ET)
Globe Newswire (Wed, 10-Dec 3:01 PM ET)
PRNewswire (Mon, 8-Dec 2:40 PM ET)
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Mersana Therapeutics trades on the NASDAQ stock market under the symbol MRSN.
As of January 6, 2026, MRSN stock price was flat at $29.08 with million shares trading.
MRSN has a beta of 1.31, meaning it tends to be more sensitive to market movements. MRSN has a correlation of 0.02 to the broad based SPY ETF.
MRSN has a market cap of $145.36 million. This is considered a Micro Cap stock.
Last quarter Mersana Therapeutics reported $11 million in Revenue and -$1.51 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.40.
In the last 3 years, MRSN traded as high as $240.50 and as low as $5.21.
The top ETF exchange traded funds that MRSN belongs to (by Net Assets): VTI, VXF, MSSM.
MRSN has underperformed the market in the last year with a price return of -16.3% while the SPY ETF gained +18.1%. However, in the short term, MRSN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +251.2% vs +3.7% return in SPY. But in the last 2 weeks, MRSN shares have been beat by the market, returning +0.6% compared to an SPY return of +1.0%.
MRSN support price is $28.60 and resistance is $29.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRSN shares will trade within this expected range on the day.
